Catherine E. Lai, MD, MPH

A look at emerging treatments and remaining unmet needs in the overall treatment landscape for acute myeloid leukemia.

Expert perspectives on some of the challenges faced in managing the treatment of patients with AML upon first remission.

A discussion about how ensuring continuity of care for patients with AML on maintenance therapy with a focus on how the care team can coordinate to ensure best outcomes.

Catherine E. Lai, MD, MPH, discusses the goals of maintenance therapy, how to manage treatment-related adverse events, and the impact of treatment on patient’s quality of life.

A review of recent data regarding maintenance therapy for patients with AML who achieve first remission, including updates from the 2023 ASH Annual meeting.

Catherine E. Lai, MD, MPH, shares her approach to treatment after a patient with AML completes induction therapy.

Insight into monitoring patients who are being treated for AML, what constitutes complete remission, and how and why it’s important to test for minimal residual disease to determine a patient’s risk for relapse.

Catherine E. Lai, MD, MPH, discusses the current standard of care in the first-line treatment of patients with AML and which factors guide therapy selection.

Expert perspectives on the role of biomarker testing in the diagnosis and management of acute myeloid leukemia.

Join Catherine Lai, MD, MPH in this informative OncLive News Network program as she explores strategies for optimizing outcomes in the long-term management of Acute Myeloid Leukemia (AML), with a focus on patients in first remission without a transplant. Here, she provides a brief overview of the current incidence of AML, its risk factors, and prognosis.

Courtney DiNardo, MD, MSCE; Eunice Wang, MD; and Jessica Altman, MD, discuss the scientific achievements they have witnessed in the field of leukemia and their hopes for the future of treating this disease.

Courtney DiNardo, MD, MSCE; Eunice Wang, MD; and Jessica Altman, MD, discuss how they turned career obstacles into opportunities and what they have learned from being women in the leukemia field.

Courtney DiNardo, MD, MSCE; Eunice Wang, MD; and Jessica Altman, MD, discuss the importance of strong mentorship relationships and the unique growth opportunities they found at different points of their careers.

Courtney DiNardo, MD, MSCE; Eunice Wang, MD; and Jessica Altman, MD, discuss the toughest challenges they faced in the leukemia field at the start of their fellowships and careers.

Selina M. Luger, MD, FRCPC, Gail J. Roboz, MD, and Wendy Stock, MD, discuss how being female affected their careers and share the scientific achievements they most want to be remembered for in the leukemia field.

Selina M. Luger, MD, FRCPC; Gail J. Roboz, MD; and Wendy Stock, MD, discuss what motivated them to continue working toward improvements in the leukemia field, even when outcomes were dismal and treatment options were scarce.

Selina M. Luger, MD, FRCPC; Gail J. Roboz, MD; and Wendy Stock, MD, discuss the challenges that accompanied the lack of progress in leukemia treatment when they began their fellowships and express their excitement about encouraging developments that have since emerged in the arena.

Judith Karp, MD; Azra Raza, MD; and Michelle M. Le Beau, PhD, share the challenges they chose to mold into career goals, including developing a new technology to study cell cytokinetics, identifying gene phenotypes, and recognizing that leukemia diseases stem from the same root issues in DNA.

Judith Karp, MD; Azra Raza, MD; and Michelle M. Le Beau, PhD, highlight the decades-long evolution of the leukemia field and express challenges such as defining the causes of leukemia and developing therapies to treat the disease and mitigate adverse effects like bone pain.